Tang Capital Management Discloses New Precigen Position, PGN Stock Up 280% in a Year

Precigen stock has surged 282% in a year, with FDA approval of PAPZIMEOS in August seen as a key factor. Tang Capital Management has disclosed a new position in Precigen, acquiring 12.4 million shares valued at $40.8 million. The company's focus on gene and cellular therapies, disease-modifying therapeutics, and biotechnological platforms has contributed to its growth. Precigen's cash position is expected to fund operations to breakeven, and more than 100 patients have already enrolled in the PAPZIMEOS Patient Hub.